FDA
-
-
-
-
-
-
-
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
-
-
-
-
-
-
-
Kiniksa Pharmaceuticals (KNSA) Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance
-
-
-
-
-
-
-
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
-
-
-
-
-
-
-
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution
-
-
-
-
-
-
-
Kiniksa Pharmaceuticals and Huadong Medicine Announce Strategic Collaboration
-
-
-
-
-
-
-
Pre-Open Stock Movers 06/09: (AEMD) (WISH) (SLDB) Higher; (ODNS) (CPB) (CMTL) Lower (more...)
-
-
-
-
-
-
-
Kiniksa Reports First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

